Form 4: Li Dean Y. Reports Share Acquisition at Recursion Pharmaceuticals

Dean Y. Li acquired 3,268 shares of Class A Common Stock in Recursion Pharmaceuticals, Inc. on April 1, 2026, as part of the company's Outside Director Compensation Policy.

Summary

• Dean Y. Li, a Director at Recursion Pharmaceuticals, Inc. (RXRX), acquired 3,268 shares of Class A Common Stock on April 1, 2026.
• These shares were issued under the company's Outside Director Compensation Policy.
• Following this transaction, Li beneficially owns 1,244,177 shares directly.
• Additionally, Li has indirect beneficial ownership of 1,422,048 shares through the Dean Y. Li Revocable Trust, 136,981 shares through the Dean Y. Li GRAT, and 421,000 shares through the Dean Y. Li 2021 Family Trust.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine disclosure of share acquisition by a director under a compensation policy, rather than a significant strategic event or financial performance update.

Positives

• Director compensation policy is in place, indicating a structured approach to incentivizing board members.
• Acquisition of shares by a director can signal confidence in the company's future prospects.
• Significant indirect beneficial ownership suggests a long-term commitment to the company.

Future Outlook

No specific future outlook or guidance is provided in this filing, as it pertains to a change in beneficial ownership by a director.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The acquisition of shares by a director under a compensation policy is a common practice in the biotechnology and pharmaceutical sectors, reflecting alignment of interests between management and shareholders.

Stakeholder Impact

• Shareholders: The acquisition by a director may be viewed positively as a sign of commitment, but the direct impact on share price is likely minimal given it's part of a compensation policy.

Key Dates

Keywords

Form 4, SEC Filing, Recursion Pharmaceuticals, RXRX, Director Compensation, Share Acquisition, Beneficial Ownership, Class A Common Stock